jsagati
1 Answer
nlnnet
For Immediate Release: Jan. 22, 2010
Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
Contact: Sandy Walsh, 301-796-4669, sandy.walsh@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA Approves Ampyra to Improve Walking in Adults with Multiple Sclerosis
The U.S. Food and Drug Administration today approved Ampyra (dalfampridine) extended release tablets to improve walking in patients with multiple sclerosis (MS). In clinical trials, patients treated with Ampyra had faster walking speeds than those treated with an inactive pill (placebo). This is the first drug approved for this use.
| 12 years ago. Rating: 0 | |
Top contributors in Uncategorized category
Unanswered Questions
OCTOBER 03, 2023. I arrived at akaQA exactly 12 years ago today.
> More questions...
Answers: 0
Views: 5
Rating: 0